Form 4: United Therapeutics CEO Executes Planned Stock Sale

CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

Summary

• Martine Rothblatt, Chairperson and CEO of United Therapeutics, exercised 9,500 stock options at a strike price of $146.03.
• Following the exercise, the CEO sold the 9,500 shares in multiple transactions on April 22, 2026.
• The sales were executed at weighted average prices ranging from $572.47 to $580.06 per share.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on November 7, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and represent routine liquidity management by the CEO.

Positives

• The transactions were executed under a pre-planned 10b5-1 program, indicating the sales were not based on non-public information.
• The CEO maintains a significant remaining beneficial ownership stake in the company, including direct and indirect holdings.

Negatives

• The sale represents a reduction in the CEO's direct equity holdings in the company.

Risks

• The 10b5-1 plan is scheduled to continue until the earlier of December 31, 2026, or the exercise of 1,734,410 stock options, which may lead to further periodic selling pressure.

Future Outlook

The reporting person's 10b5-1 plan remains active and is expected to continue until the end of 2026 or until the specified 1,734,410 options are exercised.

Management Comments

• The transactions were executed pursuant to a pre-arranged 10b5-1 trading plan adopted on November 7, 2025.

Industry Context

StockSavvy.ai notes that executive stock sales under 10b5-1 plans are standard corporate practice for liquidity and diversification, and generally do not signal a change in management's outlook on the company's long-term prospects.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for executives to sell shares while avoiding potential insider trading liability.
• The scale of the sale relative to the CEO's total holdings is consistent with typical executive compensation and liquidity management strategies in the biotech sector.

Related Party Transactions

• The filing discloses holdings held in various family trusts and by the reporting person's spouse.

Stakeholder Impact

• Shareholders should note the ongoing, systematic sale of shares by the CEO as part of a pre-planned program.

Next Steps

• Continued execution of the 10b5-1 trading plan through December 31, 2026.

Key Dates

Keywords

United Therapeutics, UTHR, Martine Rothblatt, Insider Trading, 10b5-1, Stock Options, Biotech